Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1928 1
1929 1
1932 1
1933 1
1934 1
1936 1
1937 1
1938 2
1946 2
1947 2
1948 1
1949 1
1950 1
1951 1
1952 2
1953 2
1954 3
1955 7
1956 2
1957 6
1958 2
1959 4
1960 2
1961 1
1962 2
1963 3
1964 4
1965 5
1966 8
1968 3
1969 4
1970 4
1971 15
1972 10
1973 13
1974 17
1975 13
1976 14
1977 8
1978 10
1979 6
1980 9
1981 5
1982 2
1983 3
1984 4
1985 3
1986 2
1987 1
1988 4
1989 3
1990 1
1991 2
1992 2
1993 5
1995 3
1996 4
1997 7
1998 4
1999 9
2000 8
2001 8
2002 10
2003 8
2004 11
2005 11
2006 10
2007 11
2008 8
2009 14
2010 13
2011 7
2012 14
2013 12
2014 11
2015 15
2016 25
2017 23
2018 18
2019 28
2020 34
2021 50
2022 37
2023 26
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

647 results

Results by year

Filters applied: . Clear all
Page 1
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Among authors: lehmann ff. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Among authors: lehmann ff. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.
mTOR signaling mediates ILC3-driven immunopathology.
Teufel C, Horvath E, Peter A, Ercan C, Piscuoglio S, Hall MN, Finke D, Lehmann FM. Teufel C, et al. Among authors: lehmann fm. Mucosal Immunol. 2021 Nov;14(6):1323-1334. doi: 10.1038/s41385-021-00432-4. Epub 2021 Aug 2. Mucosal Immunol. 2021. PMID: 34341503 Free PMC article.
Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. Lonez C, et al. Among authors: lehmann ff. Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4. Curr Res Transl Med. 2018. PMID: 29625833 Review.
Monitoring of therapy for inflammatory bowel disease.
Burri E, Beglinger C, Lehmann FS. Burri E, et al. Among authors: lehmann fs. Digestion. 2012;86 Suppl 1:1-5. doi: 10.1159/000341953. Epub 2012 Oct 5. Digestion. 2012. PMID: 23051719 Review.
[Changing structures--Integrating health].
Plaumann M, Lehmann F, Pawils S, Walter U. Plaumann M, et al. Among authors: lehmann f. Gesundheitswesen. 2015 Sep;77 Suppl 1:S109-11. doi: 10.1055/s-0035-1559786. Epub 2015 Sep 16. Gesundheitswesen. 2015. PMID: 26375181 German.
Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells.
Parmigiani E, Ivanek R, Rolando C, Hafen K, Turchinovich G, Lehmann FM, Gerber A, Brkic S, Frank S, Meyer SC, Wakimoto H, Günel M, Louvi A, Mariani L, Finke D, Holländer G, Hutter G, Tussiwand R, Taylor V, Giachino C. Parmigiani E, et al. Among authors: lehmann fm. Dev Cell. 2022 Aug 8;57(15):1847-1865.e9. doi: 10.1016/j.devcel.2022.06.006. Epub 2022 Jul 7. Dev Cell. 2022. PMID: 35803280 Free article.
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J. Wickström M, et al. Among authors: lehmann f. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029544 Free PMC article. Review.
647 results